Drugs / NNC0487-0111
Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT07757087 | Aug 2026 → Sep 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07587710 | May 2026 → Dec 2027 expected | obesity disorder | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07535307 | Apr 2026 → Nov 2027 expected | type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07508020 | Mar 2026 → Jan 2028 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT07121153 | Aug → Dec 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06820476 | Feb → May 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06559527 | Aug 2024 → Feb 2025 | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06461039 | Jun 2024 → Mar 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06049329 | Sep → Dec 2023 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06542874 | Aug 2024 → Oct 2025 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 2 | NCT06064006 | Sep 2023 → Nov 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 310 trials | ||||||
| Phase 3 | NCT07822061 | Sep 2026 → Feb 2029 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07400107 | May 2026 → Dec 2028 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07567001 | May 2026 → Jul 2029 expected | heart failure, obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07571005 | May 2026 → Jul 2028 expected | obesity disorder, obstructive sleep apnea syndrome | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07571109 | May 2026 → Jun 2028 expected | obesity disorder, obstructive sleep apnea syndrome | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07503210 | Apr 2026 → Jun 2028 expected | obesity disorder | Novo Nordisk A/S | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07509307 | Apr 2026 → Aug 2028 expected | obesity disorder, osteoarthritis, knee | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07481630 | Apr 2026 → Aug 2028 expected | obesity disorder, osteoarthritis, knee | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07533175 | Apr 2026 → Aug 2028 expected | obesity disorder, type 2 diabetes mellitus | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 3 | NCT07339423 | Feb 2026 → Jun 2029 expected | obesity disorder | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06478563 Comparator | Jun 2024 → Jun 2025 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0487-0111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07121153 ↗ |
| Known as | NNC0487-0111 A | “NNC0487-0111 A will be administered subcutaneously.” NCT06461039 ↗ |
| Action | Activate | “glucagon-like peptide-1 and amylin receptor agonist” PMID 42443140 ↗ Jul 2026 |
| Route | Oral | “when given as an oral tablet” NCT06049329 ↗ |